Viewing Study NCT06578702


Ignite Creation Date: 2025-12-25 @ 3:46 AM
Ignite Modification Date: 2025-12-26 @ 2:33 AM
Study NCT ID: NCT06578702
Status: RECRUITING
Last Update Posted: 2024-08-29
First Post: 2024-08-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluation of Intermittent Triple Therapies in Real Life
Sponsor: University Hospital, Strasbourg, France
Organization:

Study Overview

Official Title: Evaluation of Intermittent Triple Therapies in Real Life
Status: RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ETRIVIE
Brief Summary: The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al.

Currently this strategy is proposed by some teams in France, but is not recommended internationally.

The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: